|

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

RECRUITINGSponsored by MiraKind
Actively Recruiting
SponsorMiraKind
Started2014-09
Est. completion2030-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT02253251

Summary

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Personal or family history of cancer
* Personal history of endometriosis, or autoimmunity

Exclusion Criteria:

* Younger than 18
* Non-english speaking and unable to understand and sign the consent

Conditions2

Breast CancerCancer

Locations1 site

MiraKind
Los Angeles, California, 90025
Joanne Weidhaas, MDPhD203-671-1308joanne@mirakind.org

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.